Down Syndrome Study

About the Study

Brief Summary

Down syndrome is the most common genetic syndrome which is characterized by trisomy 21 (three copies of chromosome 21). It can affect multiple organ systems – most importantly cardiovascular, neurological, musculoskeletal. Individuals with Down syndrome have high rates of obesity (almost double than the general population) due to biological differences, food preferences, behavioral inflexibility and differences in exercise capacity. The higher rates of obesity adversely affects their risk of Type 2 diabetes, heart health, osteoarthritis, sleep apnea and mental health. While lifestyle modifications are the cornerstone of obesity management, the availability of newer FDA approved medications like Qsymia and GLP-1 analogs offers an opportunity to use these modalities for obesity management in individuals with Down syndrome. There is no data that reports the effectiveness and side effects in this population.

We are conducting an observational cohort study to evaluate the real-world efficacy and side effects in children and adults with Down syndrome.